^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

APOBEC3A (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3A)

i
Other names: APOBEC3A, Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3A, PHRBN, ARP3, Apolipoprotein B MRNA Editing Enzyme, Catalytic Polypeptide-Like 3A, DNA DC->DU-Editing Enzyme APOBEC-3A, Phorbolin-1, A3A, Probable DNA DC->DU-Editing Enzyme APOBEC-3A, Phorbolin I, BK150C2.1
Associations
Trials
5d
APOBEC3 promotes squamous differentiation via IL-1A/AP-1 signaling. (PubMed, Nat Commun)
Furthermore, single cell and spatial transcriptomics reinforces the role of APOBEC3A in fostering squamous trans-differentiation and promoting the emergence of a subpopulation of highly squamous epithelial cells. Our results demonstrate that mouse Apobec3 and human APOBEC3A promote squamous differentiation in urothelial carcinoma and that this trans-differentiation phenotype is mediated through IL-1α signaling, a target of FDA approved therapies for rheumatologic disease.
Journal
|
TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • IL1A (Interleukin 1, alpha) • APOBEC3A (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3A)
24d
Single base focal hypermutation cooccurs with structural variation as an early event in advanced prostate tumourigenesis with ancestry specific independence: a multi-ancestral observational study. (PubMed, Res Sq)
Conclusions We found kataegis-positivity to be associated with poor PCa presentation and prognosis, irrespective of patient ancestry. Kataegis-related genomic instability occurring early and late during African derived tumourigenesis, may partly explain the heightened tumour and clinical heterogeneity observed for patients of African ancestry.
Observational data • Journal
|
APOBEC3B (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3B) • APOBEC3A (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3A)
24d
APOBEC3A-Induced DNA Damage Drives Polymerase θ Dependency and Synthetic Lethality in Cancer. (PubMed, bioRxiv)
Crucially, inhibition of DNA polymerase theta (Polθ) synergizes with APOBEC3A-induced DSBs to induce synthetic lethality in vitro and in vivo . Collectively, our findings identify TMEJ as the preferred mechanism for repairing APOBEC3A-induced DSBs and establish Polθ inhibition as a novel promising strategy to eliminate cancer cells with APOBEC3A activity.
Journal
|
APOBEC3A (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3A)
2ms
Identification and characterization of lLF2 as a prognostic biomarker in HER2-positive breast cancer using Mendelian randomization and machine learning. (PubMed, Discov Oncol)
ILF2 is biologically and clinically important in HER2-positive breast cancer, and its high expression is linked with tumor immune escape and increased resistance to chemotherapeutic agents. Future studies should further explore the mechanism and application of ILF2 as a potential therapeutic target.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • LAMTOR5 (Late Endosomal/Lysosomal Adaptor) • SLC16A3 (Solute Carrier Family 16 Member 3) • APOBEC3A (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3A)
|
HER-2 positive • HER-2 expression
3ms
Analysis of the mRNA modification machinery alterations in breast cancer through the SCAN-B cohort. (PubMed, NAR Cancer)
Conversely, the m6A writer METTL14 was downregulated. Our findings highlight key mRMPs as potential biomarkers and therapeutic targets, underscoring the role of RNA modifications in breast cancer progression.
Journal
|
IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • YBX1 (Y-Box Binding Protein 1) • ADAR (Adenosine Deaminase RNA Specific) • ALYREF (Aly/REF Export Factor) • APOBEC3A (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3A) • METTL14 (Methyltransferase 14) • NSUN5 (NOP2/Sun RNA Methyltransferase 5)
4ms
APOBEC3A drives deaminase mutagenesis in human gastric epithelium. (PubMed, Genome Res)
Here, we investigated the comparative mutagenic activities of APOBEC3A and APOBEC3B, through whole-genome sequencing of human normal gastric organoid lines carrying doxycycline-inducible APOBEC expression cassettes...Further analysis of the mutational landscape following APOBEC3A upregulation revealed a detailed spectrum of APOBEC3A-associated mutations, including indels, primarily 1 bp deletions, clustered mutations, and evidence of selective pressures acting on cells carrying the mutations. Our observations provide a clear foundation for understanding the mutational impact of APOBEC enzymes in human cells.
Journal
|
TP53 (Tumor protein P53) • APOBEC3B (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3B) • APOB (Apolipoprotein B) • APOBEC3A (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3A)
|
TP53 mutation
4ms
The role of APOBEC mutagenesis in the progression and therapeutic guidance of pancreatic cancer. (PubMed, Genomics)
Our study illustrated the characterization of APOBEC mutagenesis in multiple cancer types and highlighted its potential value as a prognostic and immunotherapeutic biomarker for PAAD, and finally demonstrated the effectiveness of irinotecan, an inhibitor of APMs, in vivo and in vitro experiments.
Journal • IO biomarker
|
CD73 (5'-Nucleotidase Ecto) • ACTA2 (Actin Alpha 2 Smooth Muscle) • COL1A1 (Collagen Type I Alpha 1 Chain) • APOB (Apolipoprotein B) • APOBEC1 (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 1) • APOBEC3A (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3A)
|
irinotecan
4ms
TRDMT1 methyltransferase gene knockout attenuates STING-based cell death signaling during self-extracellular RNA-mediated response in drug-induced senescent osteosarcoma cells. (PubMed, Cell Mol Life Sci)
In the present study, self-extracellular RNA was obtained from dying (RNA D) and senescent (RNA S) cellular models of osteosarcoma (OS), characterized by NGS, and tested against proliferating and non-proliferating (etoposide-indued senescent) OS cells (U-2 OS, SaOS-2, MG-63, 143B)...TRDMT1 KO also resulted in replication stress in OS cells that was potentiated by RNA D and RNA S stimulation and associated with elevated levels of APOBEC3A and APOBEC3G, members of the cytidine deaminase protein family. In conclusion, we showed that TRDMT1 KO restricted STING-based immune and cell death response to RNA D and RNA S in non-proliferating drug resistant OS cells that might have potential therapeutic implications.
Journal
|
RAD51 (RAD51 Homolog A) • STING (stimulator of interferon response cGAMP interactor 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • APOBEC3A (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3A) • APOBEC3G (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3G) • IFNB1 (Interferon Beta 1) • NSUN5 (NOP2/Sun RNA Methyltransferase 5)
|
etoposide IV
7ms
APOBEC affects tumor evolution and age at onset of lung cancer in smokers. (PubMed, Nat Commun)
Consistently, HAS exhibit high expression of pulmonary healing signaling pathway, stemness markers, distal cell-of-origin, more neoantigens, slower clonal expansion, but no smoking-associated genomic/epigenomic changes. With validation in 184 lung tumor samples, these findings show how heterogeneity in mutational burden across co-occurring mutational processes and cell types contributes to tumor development.
Journal • Tumor mutational burden
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • APOBEC3B (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3B) • APOBEC3A (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3A)
|
TP53 mutation • KRAS mutation
7ms
Uracil-induced replication stress drives mutations, genome instability, anti-cancer treatment efficacy, and resistance. (PubMed, Mol Cell)
Unprocessed uracil can also induce replication stress directly and independently of BER by slowing down replication forks, leading to single-stranded DNA (ssDNA) gaps. In this perspective, we review how genomic uracil induces replication stress, the therapeutic implications of targeting uracil-induced vulnerabilities, and potential strategies to exploit these mechanisms in cancer treatment.
Review • Journal
|
APOBEC3A (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3A)
8ms
Defining APOBEC-induced mutation signatures and modifying activities in yeast. (PubMed, Methods Enzymol)
Here, we present validated methods utilizing yeast to determine APOBEC mutation signatures, genetic interactors, and chromosomal substrate preferences. These methods can be employed to assess the potential of other human APOBECs and APOBEC orthologs in different species to contribute to cancer genome evolution as well as define the pathways that protect the nuclear genome from inadvertent APOBEC activity during viral restriction.
Journal
|
APOBEC3B (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3B) • APOBEC3A (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3A)
8ms
An in vitro cytidine deaminase assay to monitor APOBEC activity on DNA. (PubMed, Methods Enzymol)
Denaturing gel electrophoresis is used to separate cleaved DNA from full-length DNA, enabling the quantification of the percentage of deamination induced by APOBEC3B. This protocol can be used to determine the presence of APOBEC and the regulation of APOBEC activity in specific cell lines, to study substrate preference targeted by different members of the APOBEC family and different APOBEC mutants, or to determine the efficiency and specificity of inhibitor compounds against APOBEC enzymes.
Preclinical • Journal
|
APOBEC3B (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3B) • APOBEC3A (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3A)